News articles about Amicus Therapeutics (NASDAQ:FOLD) have trended positive on Friday, according to Alpha One. The research group, a service of Accern, rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amicus Therapeutics earned a coverage optimism score of 0.37 on Alpha One’s scale. Alpha One also assigned media coverage about the biopharmaceutical company an impact score of 50 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the stock’s share price in the next few days.
These are some of the headlines that may have effected AlphaOne Sentiment Analysis’s scoring:
- Amicus Therapeutics, Inc. (FOLD) Upgraded to Buy by BidaskClub (americanbankingnews.com)
- Worth Watching Stock’s News Analysis Report : Amicus Therapeutics, Inc. (NASDAQ:FOLD),IHS Markit Ltd (NASDAQ … – Stocks In Focus (press release) (nysetradingupdates.com)
- New Data Validate Amicus’s Pompe Disease Candidate – Seeking Alpha (seekingalpha.com)
- AMICUS THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (form 8-K) (4-traders.com)
- Uptrend Call Working As Amicus Therapeutics Stock Rises 46.9% (FOLD) (mysmartrend.com)
Shares of Amicus Therapeutics (NASDAQ:FOLD) traded up 7.28% during trading on Friday, reaching $9.43. The company’s stock had a trading volume of 4,713,439 shares. The stock’s market cap is $1.35 billion. Amicus Therapeutics has a 52-week low of $4.41 and a 52-week high of $9.61. The stock’s 50 day moving average price is $7.93 and its 200-day moving average price is $6.70.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.02. The business had revenue of $4.20 million during the quarter, compared to analyst estimates of $4.16 million. Amicus Therapeutics’s revenue was up 50.0% on a year-over-year basis. Equities analysts anticipate that Amicus Therapeutics will post ($1.45) EPS for the current year.
FOLD has been the topic of a number of recent analyst reports. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 15th. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. ValuEngine raised Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Bank of America Corporation cut their price objective on Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $12.00 price objective (up from $10.00) on shares of Amicus Therapeutics in a research note on Wednesday, May 17th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $11.46.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by WKRB News and is the sole property of of WKRB News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.wkrb13.com/markets/2229348/amicus-therapeutics-fold-earning-favorable-media-coverage-alphaone-reports.html.
In other Amicus Therapeutics news, insider Hung Do sold 29,914 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $8.00, for a total value of $239,312.00. Following the completion of the sale, the insider now owns 474,438 shares in the company, valued at approximately $3,795,504. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 3.40% of the company’s stock.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229348/amicus-therapeutics-fold-earning-favorable-media-coverage-alphaone-reports.html
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.